Granules India Ltd; a fully integrated pharmaceutical company with specialisation in Pharmaceutical Formulation Intermediates (PFI), today announced the approval of its facilities in the recently conducted audit by  the US FDA (United States Food and Drug Administration). The Gagillapur PFI facility was re-audited by the FDA and approved, following the filing of an ANDA (Abbreviated New Drug Application) by one of Granules’ customers in the United States. The new API facility at Bonthapally, manufacturing 12000 MT of Acetaminophen / Paracetamol API (Active Pharmaceutical Ingredients), was audited and approved by the FDA following a special request made by Granules to schedule the inspection of this plant.

The Gagillapur facility has the capacity to manufacture 7,200 MTPA of PFI and is the site for the new tableting block of Granules with a capacity of 12 billion tablets.

Mr. Krishna Prasad, Managing Director of Granules India, commented “This approval of our Acetaminophen facility by the FDA will help us get into high-value combination products of Acetaminophen at the formulations level apart from giving the comfort to our customers that Granules adopts the highest standards of Quality Management even for a product like Acetaminophen where having an FDA inspected plant is not a pre-requisite to be a supplier.”

Sourced From: Prana Public Relations